The Ticker: After Delays, Teva to Launch Key Migraine Treatment in mid-September

Delek Royalties meets strong demand in maiden bond sale ■ Marijuana shares plummet after exchange refuses to include Together in share indices ■ Pointer teaming up with Microsoft to use AI to understand driver behavior ■ Insurance and energy shares weigh on Tel Aviv market

comments Print
After delays, Teva expects to launch key migraine treatment in mid-September